OKYO Pharma Announces Data In Long-Term Stability Of Urcosimod; Urcosimod In Phase 2 Clinical Trial For Neuropathic Corneal Pain Shown To Have Long-Term Stability

• Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term Stability
• Urcosimod stable in single-use ampoules for more than 2½ years
• FDA requires drug to show long-term shelf stability for approval
• Daily administration to patients via ampoules can minimize risk of contamination

LONDON and NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that the Company has successfully established that urcosimod (formerly known as OK-101) has been shown to be stable for over two and a half years in single-use ampoules used for administration of the drug to patients. Urcosimod is presently in a Phase 2b, randomized, placebo-controlled, double-masked, 48-patient clinical trial to treat NCP patients.